First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

MLA

Piha-Paul, Sarina A., et al. “First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.” Oncologist, vol. 29, no. 4, Apr. 2024, pp. e514–25. EBSCOhost, https://doi.org/10.1093/oncolo/oyad338.

APA

Piha-Paul, S. A., Xu, B., Dumbrava, E. E., Fu, S., Karp, D. D., Meric-Bernstam, F., Hong, D. S., Rodon, J. A., Tsimberidou, A. M., Raghav, K., Ajani, J. A., Conley, A. P., Mott, F., Fan, Y., Fan, J., Peng, P., Wang, H., Ni, S., Sun, C., & Qiang, X. (2024). First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist, 29(4), e514–e525. https://doi.org/10.1093/oncolo/oyad338

Chicago

Piha-Paul, Sarina A, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp, Funda Meric-Bernstam, David S Hong, et al. 2024. “First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.” Oncologist 29 (4): e514–25. doi:10.1093/oncolo/oyad338.